JP2003535024A5 - - Google Patents

Download PDF

Info

Publication number
JP2003535024A5
JP2003535024A5 JP2001505934A JP2001505934A JP2003535024A5 JP 2003535024 A5 JP2003535024 A5 JP 2003535024A5 JP 2001505934 A JP2001505934 A JP 2001505934A JP 2001505934 A JP2001505934 A JP 2001505934A JP 2003535024 A5 JP2003535024 A5 JP 2003535024A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001505934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/017842 external-priority patent/WO2001000225A1/en
Publication of JP2003535024A publication Critical patent/JP2003535024A/ja
Publication of JP2003535024A5 publication Critical patent/JP2003535024A5/ja
Pending legal-status Critical Current

Links

JP2001505934A 1999-06-29 2000-06-28 Hla結合ペプチドおよびそれらの使用 Pending JP2003535024A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14142299P 1999-06-29 1999-06-29
US60/141,422 1999-06-29
PCT/US2000/017842 WO2001000225A1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Publications (2)

Publication Number Publication Date
JP2003535024A JP2003535024A (ja) 2003-11-25
JP2003535024A5 true JP2003535024A5 (enExample) 2005-05-26

Family

ID=22495620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001505934A Pending JP2003535024A (ja) 1999-06-29 2000-06-28 Hla結合ペプチドおよびそれらの使用

Country Status (6)

Country Link
EP (2) EP1189624A4 (enExample)
JP (1) JP2003535024A (enExample)
AT (1) ATE512666T1 (enExample)
AU (1) AU5898400A (enExample)
CA (1) CA2370413A1 (enExample)
WO (1) WO2001000225A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20040096445A1 (en) * 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
CA2377525A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
JP4776131B2 (ja) 1999-11-18 2011-09-21 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関連方法
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
ATE530193T1 (de) * 2000-05-12 2011-11-15 Northwest Biotherapeutics Inc Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen
ES2559002T3 (es) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
PT1620456E (pt) * 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP2007277092A (ja) * 2004-06-17 2007-10-25 Univ Kurume 前立腺関連抗原由来hla−a2結合性ペプチド
EP1840133A1 (en) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. New immunomodulating oligopeptides
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US8282938B2 (en) * 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
US9249187B2 (en) * 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
US10155036B2 (en) * 2014-02-28 2018-12-18 Emergex Vaccines Holding Ltd. MHC class I associated peptides for prevention and treatment of hepatitis B virus infection
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
WO2018065625A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
NL2019814B1 (en) * 2017-10-26 2019-05-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Methods for producing a MHC multimer.
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
SI3773689T1 (sl) 2018-04-11 2023-02-28 Enterome S.A. Antigenski peptidi za preprečevanje in zdravljenje raka
EP3810182A4 (en) 2018-06-19 2022-08-24 BioNTech US Inc. Neoantigens and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン,インコーポレイティド Hla−a2.1結合ペプチドおよびそれらの使用
CA2168583C (en) * 1993-08-02 2007-10-02 Francis V. Chisari Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
AU6140998A (en) * 1997-01-31 1998-08-25 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
CA2400215A1 (en) * 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses

Similar Documents

Publication Publication Date Title
JP2003535024A5 (enExample)
JP2004512810A5 (enExample)
JP2004504166A5 (enExample)
JP2002537376A5 (enExample)
JP2004506411A5 (enExample)
JP2004057413A5 (enExample)
JP2001194586A5 (enExample)
JP2000195544A5 (enExample)
JP2001201887A5 (enExample)
JP2003221429A5 (enExample)
JP2004161990A5 (enExample)
JP2002536520A5 (enExample)
JP2002029946A5 (enExample)
JP2004505993A5 (enExample)
JP2003516137A5 (enExample)
JP2004527449A5 (enExample)
JP2004513102A5 (enExample)
JPH11323020A5 (enExample)
JPH11228682A5 (enExample)
JP2003527336A5 (enExample)
JP2001199955A5 (enExample)
JP2002053846A5 (enExample)
JP2002097406A5 (enExample)
JP2003183506A5 (enExample)
JP2003154400A5 (enExample)